ArticleBMC public health2017
The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study.
Article in BMC public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 71 citations in OpenAlex.
- Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.Blood advances · 2023Trial
- The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.PloS one · 2022Trial
- A report of novel inactivating missense mutations of BRCA1 detected in patients with acute myeloid leukemia.Journal of medical case reports · 2026Article
- Cytogenetic Profile of Newly Diagnosed Acute Myeloid Leukemia Patients: Insights from a Study at a Tertiary Care Centre in South India.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Review
- Ginsenoside Rd Induces Differentiation of Myeloid Leukemia Cells via Regulating ERK/GSK-3β Signaling Pathway.Chinese journal of integrative medicine · 2024Article
- Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study.PloS one · 2024Article
- Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study.JCO global oncology · 2023Article
- Lymphohematopoietic cancer mortality among Korean semiconductor manufacturing workers.BMC public health · 2023Article
- Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia.Frontiers in oncology · 2023Article
- Incidence and Risk Factors of Acute Leukemias in Armenia: A Population-Based Study.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.Current oncology (Toronto, Ont.) · 2022Article
- Genetic Profiles and Risk Stratification in Adult De Novo Acute Myeloid Leukaemia in Relation to Age, Gender, and Ethnicity: A Study from Malaysia.International journal of molecular sciences · 2021Article
- Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation.JCO global oncology · 2021Review
- Clinicopathological Evaluation of Acute Leukemias in a Tertiary Care Hospital: A Cross-Sectional Study.Turk patoloji dergisi · 2021Observational
- Article
- Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.International journal of molecular sciences · 2020Article
- Increased Risk of Acute Myelogenous Leukemia After Early Onset but Not Late-Onset Colorectal Cancer.American journal of clinical oncology · 2020Article
- Article
- Prospective evaluation of clinical symptoms of chemotherapy-induced oral mucositis in adult patients with acute leukemia: A preliminary study.Clinical and experimental dental research · 2020Observational
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe incidence rate of acute myeloid leukemia (AML) was determined in the Calgary Metropolitan Area, a major Canadian city.
methodsData from all patients diagnosed with AML between January 1, 2011 and December 31, 2015 were retrieved from a single, centralized cancer cytogenetics laboratory for bone marrow samples, the sole diagnostic facility of its kind in Southern Alberta.
resultsThe calculated incidence rate was 2.79 cases per 100,000 person-years with a median age of 60, slightly lower than previously published data. The age-standardized incidence rate for Canada was 3.46 cases per 100,000 person-years. The higher value is reflective of Calgary's younger population compared to the rest of Canada. Higher male incidence and greatest incidence occurring at approximately the age of 85 is similar to data from other developed countries. The lower incidence rates and median age of diagnosis, in comparison with that of other high-income nations, may be due to differences in the proportion of aging citizens in the population.
conclusionThis is the first published incidence rate of acute myeloid leukemia (AML) in Canada across all age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.